Pemexen Injection 500 mg/20 ml contains Pemetrexed, an advanced chemotherapy agent used for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Pemetrexed is classified as a multi-targeted antifolate, which interferes with cancer cell growth by inhibiting enzymes essential for DNA and RNA synthesis.

This high-dose formulation allows for precise dosing in hospital settings, typically administered via intravenous infusion. Pemetrexed disrupts folate-dependent metabolic pathways, preventing rapidly dividing tumor cells from replicating, thereby slowing tumor progression and promoting cancer cell death. It is often used as first-line therapy in combination with cisplatin or as maintenance therapy in advanced NSCLC.

Pemexen Injection 500 mg/20 ml provides a convenient and sterile solution for clinical administration, ensuring controlled delivery, accurate dosing, and effective cancer management under oncologist supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features

• Contains Pemetrexed 500 mg per 20 ml of sterile solution

• Multi-targeted antifolate for malignant pleural mesothelioma and NSCLC

• Intravenous infusion for controlled hospital administration

• Inhibits DNA and RNA synthesis, targeting rapidly dividing tumor cells

• Can be used as monotherapy or in combination with other chemotherapeutic agents

• Ensures precise, high-dose treatment under medical supervision

Indications

Pemexen Injection 500 mg/20 ml is indicated for:

• Malignant pleural mesothelioma: First-line therapy, commonly combined with cisplatin

• Non-small cell lung cancer (NSCLC): Maintenance therapy or treatment of advanced stages

• Other off-label uses: Only under strict oncologist supervision

Individualized dosing and close monitoring are essential for safe and effective therapy.

Mechanism of Action

Pemetrexed works as a multi-targeted antifolate by inhibiting key enzymes in nucleotide synthesis:

• Thymidylate synthase (TS): Reduces DNA synthesis

• Dihydrofolate reductase (DHFR): Prevents regeneration of tetrahydrofolate

• Glycinamide ribonucleotide formyltransferase (GARFT): Inhibits purine synthesis

By disrupting DNA and RNA production, Pemetrexed selectively targets cancer cells while minimizing damage to normal tissue.

Dosage and Administration

• Administered via intravenous infusion over 10 minutes or more, as per oncologist instructions

• Dosage is based on body surface area (mg/m²); typically 500 mg/m² every 21 days

• Pre-treatment with folic acid, vitamin B12, and corticosteroids is required to reduce toxicity

• Continuous monitoring of blood counts, liver, and kidney function is essential

• Only to be used in hospital or oncology clinic settings by trained personnel

Possible Side Effects

Common side effects:

• Fatigue, weakness

• Nausea, vomiting, or diarrhea

• Loss of appetite

• Hair thinning

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Mouth sores (mucositis)

Serious side effects (rare):

• Severe infections due to immunosuppression

• Liver or kidney dysfunction

• Allergic reactions

• Gastrointestinal perforation

Prompt medical attention is required for any severe or unusual symptoms.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Administer only under oncologist supervision in a controlled hospital environment

• Monitor blood counts and organ function regularly

• Avoid live vaccines during treatment

• Inform the doctor of all concurrent medications to prevent interactions

• Not recommended during pregnancy or breastfeeding

Storage Instructions

• Store at 2–8°C in a cool, dry place

• Protect from light

• Keep in original vial until use

• Keep out of reach of children.